Pharma BD Deal Intelligence
Pfizer acquired Trillium Therapeutics for $2.3B for immuno-oncology portfolio.
Pfizer to acquire Trillium Therapeutics Inc for $18.50 per share in cash representing implied equity value of $2.26 billion for CD47-SIRPa immuno-oncology…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Pfizer acquired Trillium Therapeutics for approximately $2.26 billion ($18.50 per share) in an all-cash merger (closed November 17, 2021), gaining maplirpacept (TTI-622 / PF-07901801) and TTI-621 (PF-07901800), next-generation SIRPalpha-CD47 checkpoint inhibitors for hematological malignancies. Post-close the franchise underperformed: by May 2026 Pfizer had terminated its remaining maplirpacept clinical trials (NCT03530683 ended August 2024 and NCT05896163 ended May 2026, both cited as business decisions to pursue other oncology programs; a Phase 2 DLBCL study was terminated July 2025 for inability to recruit), and TTI-621 was discontinued. No active maplirpacept studies remain in the registry, leaving the $2.26B acquisition without a surviving clinical program — part of an industry-wide retreat from the CD47 pathway.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Trillium Therapeutics Inc. (this deal) | 2021 | $2.3B | 21 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2021 deals · Pfizer Inc. deals · Oncology deals